



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients

Dáfne Cardoso Bourguignon da Silva^a, Gláucia Toribio Finoti Seixas^a,
Orlei Ribeiro de Araujo^{a,*}, Rodrigo Genaro Arduini^a,
Fabianne Altruda de Moraes Costa Carlesse^b, Antonio Sergio Petrilli^c

^a Intensive Care Unit, Grupo de Apoio ao Adolescente e a Criança com Câncer, Instituto de Oncologia Pediátrica, Universidade Federal de São Paulo (GRAACC-IOP-UNIFESP), São Paulo, SP, Brazil

^b Infection Control Committee GRAACC/IOP/UNIFESP, São Paulo, SP, Brazil

^c Department of Pediatrics, UNIFESP, São Paulo, SP, Brazil

ARTICLE INFO

Article history:

Received 23 January 2012

Accepted 6 May 2012

Keywords:

Immunosuppression

Drug resistance

Microbial

Staphylococcus

Anti-bacterial agents

Pharmacokinetics

ABSTRACT

Background: Usual treatment regimens with vancomycin often fail to provide adequate serum levels in patients with severe infections.

Methods: Retrospective analysis of vancomycin trough serum measurements. The following parameters were calculated by Bayesian analysis: vancomycin clearance, distribution volume, and peak estimated concentrations. The area under the concentration curve (AUC) (total daily dose/24 h clearance of vancomycin) was used to determine the effectiveness of treatment through the ratio of AUC/minimum inhibitory concentration (MIC) above 400, using MIC = 1 µg/mL, based on isolates of *Staphylococci* in cultures.

Results: Sixty-one vancomycin trough measurements were analyzed in 31 patients. AUC/MIC > 400 was obtained in 34 out of 61 dosages (55.7%), but the mean vancomycin dose required to achieve these levels was 81 mg/kg/day. In cases where the usual doses were administered (40–60 mg/kg/day), AUC/MIC > 400 was obtained in nine out of 18 dosages (50%), in 13 patients. Trough serum concentrations above 15 mg/L presented a positive predictive value of 100% and a negative predictive value of 71% for AUC/MIC > 400.

Conclusion: Higher than usual vancomycin doses may be required to treat staphylococcal infections in children with oncologic/hematologic diseases. Since the best known predictor of efficacy is the AUC/MIC ratio, serum trough concentrations must be analyzed in conjunction with MICs of prevalent *Staphylococci* and pharmacokinetic tools such as Bayesian analysis.

© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de [CC BY-NC-ND](#)

* Corresponding author at: Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC)/Instituto de Oncologia Pediátrica (IOP)/Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 743, São Paulo, SP, 04023-062, Brazil.

E-mail address: orlei@uol.com.br (O. Ribeiro De Araujo).

1413-8670 © 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de [CC BY-NC-ND](#)

<http://dx.doi.org/10.1016/j.bjid.2012.06.011>

Introduction

Children with cancer suffer the effects of immune suppression caused by chemotherapy and by the disease itself. Prolonged hospitalizations, frequent use of broad-spectrum antibiotics, the need for long-term central venous catheters, and loss of mucous membrane and skin integrity also contribute to elevated risk of severe infections.¹ Among neutropenic patients, 15% to 25% develop bloodstream infections and, frequently, they also develop infections of the respiratory and urinary tracts, skin, and digestive system.² Available data show that Gram-positive bacteria cause 45% to 70% of the bloodstream infections in neutropenic patients. The most commonly isolated Gram-positive bacteria are coagulase-negative staphylococci and *Staphylococcus aureus*, besides *Enterococcus*.³ Almost all *Staphylococcus* strains isolated from cancer patients are methicillin-resistant, and vancomycin is the drug of choice for these infections. Teicoplanin, a glycopeptide whose effectiveness is similar to vancomycin, still has a limited use due to higher cost. New and expensive agents with proven efficacy against staphylococci, such as linezolid, quinupristine-dalfopristine, and tigecycline also have limited data regarding use in children.⁴

Vancomycin exhibits a complex pharmacokinetics, with time-dependent bactericidal effect and moderate post-antibiotic effect. It also has poor tissue penetration, and some authors question its effectiveness in severe infections.^{5,6} The consensus is that the obtainment of serum free-vancomycin levels four to five times the minimal inhibitory concentration (MIC) or a ratio of area under curve (AUC) of concentration versus time/MIC above 400 is essential to achieve bacterial eradication and clinical success.⁷ For methicillin-resistant *Staphylococcus aureus* strains with MIC above 2 µg/mL, vancomycin is not effective; considering the binding to serum proteins of around 50%, trough levels of vancomycin should be 15 to 20 µg/mL to reliably eradicate strains with a MIC of 2 µg/mL. The trough level is the minimal serum concentration obtained within 30 minutes to one hour before the subsequent dose, after drug serum stabilization (usually after the fourth dose). Only a fraction (20% to 30%) of the vancomycin serum concentration can be obtained in pulmonary tissue, so higher doses are required to treat pneumonia.^{4,8} Other sites, such as bones, cardiac vegetations, and tissues around prosthetic devices, also have limited penetration.⁹

The usual vancomycin regimens frequently fail to provide minimal serum levels of 15 µg/mL. Kitzis and Goldstein analyzed serum concentrations in adults (n = 1,737) who received usual doses of 2 to 6 g/day. Adequate levels to treat susceptible methicillin-resistant *Staphylococcus aureus* (MIC up to 2 µg/mL) were obtained in 81% of the patients, but only in 20.9% to treat intermediate-sensitivity strains (MIC 2–8 µg/mL). In 780 patients, levels under 10 µg/mL were observed 36 to 48 hours after the beginning of treatment.¹⁰ Alternative regimens which could optimize the pharmacodynamics have been proposed, such as elevation of the intermittent doses and continuous infusion.¹¹ Administration of higher doses can provide effective serum levels, but the risk of nephrotoxicity may be unacceptable with doses higher than 4 g/day in adults.¹²

The vancomycin ideal therapeutic regimen for cancer patients has not yet been determined and has been poorly studied. The aims of this study were to analyze the vancomycin estimated clearance and obtained serum levels in children and adolescents with cancer, in order to evaluate the suitability of usual dosing regimens for this population.

Methods

This was a retrospective study, including oncologic/hematologic patients, hospitalized at the intensive care unit of this hospital, or submitted to bone marrow transplantation, who used vancomycin in the year 2010. The study was approved by the institutional research ethics committee (protocol number 1913/2010). Because of its retrospective characteristics, the informed consent was waived.

Vancomycin was measured with a particle enhanced turbidimetric inhibition immunoassay: free vancomycin in the serum competes with particle-bound vancomycin for drug-specific antibody binding sites, thereby inhibiting antibody-mediated particle aggregation. The rate and amount of particle aggregation are inversely proportional to the amount of vancomycin present in the sample.¹³ Blood samples were obtained one hour before the subsequent dose, in steady-state, which is at least after the fourth dose of vancomycin. Using anthropometric data and vancomycin trough measurements, the following parameters were calculated by Bayesian analysis: vancomycin clearance, distribution volume, and peak estimated concentration. Calculations were made using an open-source pharmacokinetics software (JPKD-College of Pharmacy, Kaoshiung Medical University-Taiwan). The area under the curve (AUC) of vancomycin concentration, defined as total daily dose/24 h vancomycin clearance, was analyzed. The effectiveness of the regimen was evaluated by obtaining an AUC/MIC ratio above 400. The value of MIC used for calculations was the mode (i.e., the most frequent value) of all MICs obtained from isolated *Staphylococcus* strains in culture samples of study patients. MIC was determined by agar diffusion or automated MIC (BD Phoenix™ Automated Microbiology System). The Statistical Package for Social Sciences (SPSS) version 10.1 (Pearson's correlation test and descriptive statistics) and Microsoft Excel (linear regression and graphics) softwares were used for statistical analysis.

Results

Sixty-one vancomycin serum levels were analyzed in 31 patients. The general characteristics, clearance values, and vancomycin concentrations are depicted in Table 1. Diagnoses of patients are shown in Table 2.

Coagulase-negative staphylococci were isolated from seven blood cultures and in two skin wound cultures. *S. aureus* was isolated from two blood cultures and in one tracheal aspirate sample. Other staphylococci isolated from blood cultures were *S. epidermidis* (2), *S. hominis* (1), and *S. haemolyticus* (2). Of all isolates, only four were methicillin-sensitive. The MICs observed ranged from 0.5 to 1.5, and the most frequent value was 1 µg/mL, found in seven isolates. This was the mode value used in the analysis of the AUC/MIC quotient.

Table 1 – Characteristics of the pediatric oncology/hematology patients.

Age (mean, range)	7 years (2m-13y)
Gender (male-female)	14-17
Weight in kg (mean, range)	22 (5-62)
Vancomycin clearance (mean ± SD, range)	0.18 ± 0.11 (0.067-0.48)
Distribution volume (mean ± SD)	1.03 ± 0.12
Serum creatinine (mean ± SD)	0.44 ± 0.18
Serum albumin	3.67 ± 0.51
Estimated creatinine clearance (mL/min, Schwartz, mean ± SD)	136 ± 44.8
Measured vancomycin trough serum levels (mean ± SD)	16.11 ± 11.3
Estimated peak vancomycin serum levels (mean ± SD)	29.33 ± 11.6

SD, standard deviation.

AUC/MIC results >400 were obtained in 34 of 61 dosages (55.7%), but the mean vancomycin dose to achieve this ratio was 81 mg/kg/day (range: 10-156 mg/kg/day). When the usual vancomycin dose was administered (40-60 mg/kg/day), AUC/MIC > 400 was obtained in nine of 18 dosages (50%), from 13 patients.

AUC/MIC > 400 was observed on 11 occasions in which the trough levels were below 15 mg/L (18%). However, in all instances where levels were above 15 mg/L, the AUC/MIC was always >400, i.e., trough levels above 15 mg/L have a positive predictive value of 100% and a negative predictive value of 71% for the population studied and at current rates of bacterial sensitivity to MIC of 1 µg/mL. The calculated vancomycin clearance by Bayesian analysis presented a stronger correlation with serum creatinine levels (Pearson's correlation coefficient: -0.67, p < 0.0001) than with creatinine clearance levels estimated with the Schwartz formula¹⁴ (Pearson's correlation coefficient: 0.40, p = 0.001). Figs. 1 and 2 show the linear adjustment lines (simple regression). The best-fit line equation of vancomycin clearance in relation to creatinine was: vancomycin clearance = (-0.365 × serum creatinine) + 0.3427. This equation could predict the values of vancomycin clearance using serum creatinine with a ±20% precision in 41% of the analyzed cases. No significant correlation between




Fig. 1 – Linear regression of serum creatinine and vancomycin clearance.

albumin levels and vancomycin clearance or distribution volume was observed.

Two patients (6.4%) had increased creatinine levels above 50% with vancomycin doses higher than usual. The greatest change was observed in an 8-year-old patient with baseline creatinine of 0.4, which rose to 0.73 with a vancomycin dose of 83 mg/kg/d.

Table 2 – Oncology/hematology diagnoses (n).

Acute lymphoblastic leukemia + bone marrow transplantation (2)
Acute lymphoblastic leukemia (6)
Acute myeloblastic leukemia (3)
Adrenal cortical carcinoma (1)
Astrocytoma (1)
B-cell lymphoma (1)
Botryoid rhabdomyosarcoma (1)
Brainstem primitive neuroectodermal tumor (2)
Burkitt lymphoma (1)
Craniopharyngioma (2)
Ependymoma (1)
Fanconi anemia + allogeneic BMT (1)
Forearm rhabdomyosarcoma (1)
Hepatoblastoma (1)
Infantile fibrosarcoma (1)
Medullary aplasia + allogeneic BMT (1)
Medulloblastoma (1)
Neuroblastoma + Pepper syndrome (1)
Optic nerve glioma (1)
Oropharynx undifferentiated carcinoma (1)
Rhinopharynx carcinoma (1)




Fig. 2 – Linear regression of creatinine clearance estimated with the Schwartz formula and vancomycin clearance.

Discussion

Piro et al. analyzed vancomycin serum levels in 56 oncologic patients, submitted to bone marrow transplantation, and observed that the number of patients with under-therapeutic levels was significantly higher than those who achieved therapeutic levels. These authors concluded that higher doses are needed in oncologic patients with normal renal function.¹⁵ This fact can be explained by what was observed in the present patient sample, which demonstrated vancomycin clearances and distribution volumes superior to those previously reported. Lamarre et al. described a mean clearance of 0.103 L/h/kg, in a population of 98 general pediatric patients, with a mean distribution volume of 0.43 L/kg.¹⁶ The present values were, respectively, 0.18 L/h/kg and 1.02 L/kg.

The proportion of patients in which vancomycin therapeutic levels were obtained with usual doses was similar to that reported in adults by Lepe et al. (50%).¹⁷

Vancomycin induces bacterial death in a time-dependent manner, with a moderate post-antibiotic effect. The necessary dose to achieve recommended serum levels can be extremely high, with increasing possibility of nephrotoxicity.¹⁸ In an effort to establish a mathematical model that could quickly suggest the ideal dose for adults with malignant hematologic diseases, Buelga et al. analyzed data from 215 patients with 1,004 serum dosages of vancomycin. It was observed that the patient weight was strongly correlated with distribution volume, while creatinine clearance and the diagnosis of acute myeloblastic leukemia influence vancomycin clearance. The authors proposed the following general model to estimate vancomycin clearance (Vclear): $Vclear = 1.08 \times \text{estimated creatinine clearance}$. The equation for distribution volume (DV) was: $DV = 0.98 \times \text{weight (kg)}$. This model was able to predict vancomycin clearance with a precision of $\pm 20\%$ in 33% of cases.¹⁹

In the present sample, the parameter that showed a better correlation with vancomycin clearance was serum creatinine, and the model derived from the fitting line was able to predict the clearance in 41% of cases (similar to the 33% found by Buelga et al.¹⁹), with a tendency to overestimate the lower values. Estimating the creatinine clearance with the Schwartz's formula showed no utility. It must be observed that Buelga's model presented, according to the authors, at least two times more precision than the normally utilized nomograms. Pharmacokinetic Bayesian analysis can allow individual adjustments and could be more useful than the pure mathematical models. From a single serum measure of creatinine and vancomycin at steady-state (at any moment after the fourth dose and after the drug distribution phase, one to two hours after the end of infusion), it is theoretically possible to estimate the ideal dose required to achieve the intended trough levels.¹⁷ This approach could avoid the inconvenience of raising the dose by trial and error and reduce the costs of multiple measures and the risk of nephrotoxic supratherapeutic levels, but prospective studies are lacking. Because of its complexity, Bayesian analysis demands specific softwares to be accessible to clinicians. Some commercial options are available, with moderate to high cost, and the JPKD software is free.

The highest doses used were relatively well tolerated, with only 6.4% of patients having significant elevations of serum creatinine.

Conclusion

This study shows that higher than usual vancomycin doses may be required to treat staphylococcal infections in children with oncologic/hematologic diseases. Since the best known predictor of efficacy is the AUC/MIC ratio, serum trough levels must be analyzed in conjunction with MICs of prevalent Staphylococci and pharmacokinetic tools such as Bayesian analysis.

Conflict of interest

All authors declare to have no conflict of interest.

Acknowledgements

The authors like to thank Yung-jin Lee, PhD, and the JPKD team, College of Pharmacy, Kaoshiung Medical University, Taiwan.

REFERENCES

- Bailey LC, Reilly AF, Rheingold SR. Infections in pediatric patients with hematologic malignancies. *Semin Hematol*. 2009;46:313-24.
- Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis*. 2003;36:1103-10.
- Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. *Clin Infect Dis*. 2005;40 Suppl 4:S246-52.
- Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant *Staphylococcus aureus* infections: efficacy and toxicity. *Arch Intern Med*. 2006;166:2138-44.
- Reis AG, Grisi SJ. Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections. *J Pediatr (Rio J)*. 1996;72:225-9.
- Deresinski S. Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for *Staphylococcus aureus* infections? *Int J Antimicrob Agents*. 2009;34 Suppl 4:S43-6.
- Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering Jr RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *J Clin Microbiol*. 2004;42:2398-402.
- Cruciani M, Gattr G, Lazzarini L, Furlan G, Broccali G, Malena M, et al. Penetration of vancomycin into human lung tissue. *J Antimicrob Chemother*. 1996;38:865-9.
- Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant *Staphylococcus aureus* (MRSA) and

- vancomycin-susceptible MRSA. *Antimicrob Agents Chemother.* 2009;53:3447-52.
10. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. *Clin Microbiol Infect.* 2006;12:92-5.
 11. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. *Antimicrob Agents Chemother.* 2009;53:1863-7.
 12. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. *Antimicrob Agents Chemother.* 2008;52:1330-6.
 13. Simons SA, Molinelli AR, Sobhani K, Rainey PM, Hoofnagle AN. Two cases with unusual vancomycin measurements. *Clin Chem.* 2009;55:578-82.
 14. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. *J Pediatr.* 1984;104:849-54.
 15. Piro CC, Crossno CL, Collier A, Ho R, Koyama T, Frangoul H. Initial vancomycin dosing in pediatric oncology and stem cell transplant patients. *J Pediatr Hematol Oncol.* 2009;31:3-7.
 16. Lamarre P, Lebel D, Ducharme MP. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. *Antimicrob Agents Chemother.* 2000;44:278-82.
 17. Lepe JA, Gil-Navarro MV, Santos-Rubio MD, Bautista J, Aznar J. Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to *Staphylococcus aureus* methicillin resistant. *Rev Esp Quimioter.* 2010;23:43-7.
 18. Petrosillo N, Drapeau CM, Agrafiotis M, Falagas ME. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. *Minerva Anestesiol.* 2010;76:509-24.
 19. Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, García MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. *Antimicrob Agents Chemother.* 2005;49:4934-41.